Verve’s Base Editing Hold Lifted, Starting a Thaw on a Regulatory Blockade That Sent Peers Ex-US

A nearly year-long clinical hold on Verve Therapeutics’ base editing therapy meant to treat a genetic form of high cholesterol has been lifted in the US, thanks to data from an ongoing human trial elsewhere in the world and some preclinical work that has allayed the FDA’s concerns.